Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Akebia Therapeutics (AKBA) Misses Q3 EPS by 25c
November 5, 2020 8:19 AM ESTAkebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.42), $0.25 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $60 million versus the consensus estimate of $84.9 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
... More